Ethos Technologies Inc. Class A Common Stock (LIFE) has upcoming FDA regulatory milestones for Efzofitimod. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by Ethos Technologies Inc. Class A Common Stock (LIFE).
Over the past two years, Ethos Technologies Inc. Class A Common Stock has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
ATYR0101 and Efzofitimod. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
ATYR0101 FDA Regulatory Events
ATYR0101 is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: For the treatment of interstitial lung disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ATYR0101
- Announced Date:
- October 13, 2026
- Indication:
- For the treatment of interstitial lung disease
Announcement
aTyr Pharma, Inc. announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry.
Read Announcement
Efzofitimod FDA Regulatory Timeline and Events
Efzofitimod is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Efzofitimod
- Announced Date:
- September 24, 2026
- Target Action Date:
- Q4 2026
- Estimated Target Date Range:
- October 1, 2026 - December 31, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that the Company expects to initiate study-related activities in the fourth quarter of 2026.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- September 24, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- September 1, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- July 15, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that the Company will present a subgroup analysis of the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, at the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) 2026 Congress, which is scheduled to take place July 15 – 17, 2026, in Porto, Portugal.
AI Summary
aTyr Pharma said it will present a subgroup analysis from its Phase 3 EFZO-FIT™ study of efzofitimod at the 2026 WASOG Congress in Porto, Portugal, from July 15 to 17, 2026. The analysis focuses on patients with pulmonary sarcoidosis, a serious form of interstitial lung disease that can make breathing harder over time.
According to the company, patients with restrictive lung disease showed clinically meaningful improvement in forced vital capacity, or FVC, along with better results on multiple patient-reported outcome measures when treated with 5.0 mg/kg efzofitimod compared with placebo. These findings suggest the drug may help improve lung function and symptoms in this hard-to-treat group.
aTyr also said it submitted a protocol to the FDA in June 2026 for a planned Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The poster details will be available on the company’s website after the presentation.
Read Announcement
Free LIFE Stock Alerts